INTRODUCTION
============

The transradial intervention (TRI) has several advantages, such as reduction of bleeding risk, improvement of patients\' convenience, and immediate ambulation, as compared with transfemoral intervention (TFI).[@B1] However, the TRI is associated with longer learning curve[@B2] and increased fluoroscopy time, compared with TFI.[@B3] In TRI, there are some anatomical and technical differences between the right radial approach (RRA) and the left radial approach (LRA).[@B4][@B5] The aim of this study was to evaluate the impact of the choice of the RRA or the LRA on procedural and in hospital complications, as well as 12-month clinical outcomes, in patients undergoing TRI.

MATERIALS AND METHODS
=====================

Study population
----------------

The Korean TRI registry was used for this retrospective, observational study. A total of 1653 consecutive patients of 12 centers were enrolled in this study between November 2004 to October 2010. Patients were divided into two groups: the RRA group (n=792 patients) and the LRA group (n=861 patients). Since the baseline characteristics between two groups were not matched due to adjust potential confounders, propensity score matched (PSM) analysis was performed using a logistic regression model. After PSM, a total of 1100 patients were enrolled for this analysis. Detailed data on demographics, medical history, coronary anatomy, procedural process, procedural events, pharmacotherapy, and clinical outcomes from the index procedure were collected using a standardized reporting form. This study received approval from each Institutional Review Board.[@B6]

Study outcomes
--------------

We accessed clinical outcomes and safety outcomes at 12 months after the index procedure, which were determined before the registry was started.[@B6] Clinical outcomes were major adverse cardiac events (MACE), composed of all-cause mortality, myocardial infarction (MI), target vessel revascularization (TVR), and stroke. All-cause mortality consisted of cardiac and noncardiac deaths. MI was defined as a creatine kinase value of \>three times the upper normal limit. TVR was defined as any repeated previous percutaneous coronary intervention (PCI) or bypass surgery of any segment of the target vessel. Stroke was defined as a clinical neurologic deficit from hemorrhagic or ischemic neurologic insult. The safety outcomes were based on the rate of major bleeding. Major bleeding was defined as one of the following: bleeding requiring transfusion of \>2 units of packed cells or bleeding that was fatal.[@B7] Fatal bleeding included the following: intracranial bleeding, one that brought about reduction in the hemoglobin level of \>5 g/dL or led to substantial hypotension requiring the use of intravenous inotropic agents, one that required surgical intervention, or one that required transfusion of \>4 units of packed cells.[@B8] Vascular access related bleeding was defined as one that was related to surgical or procedural interventions, such as access artery dissection, perforation, arteriovenous fistula, pseudoaneurysm or local hematoma requiring transfusion.

Statistics
----------

The covariates that were adjusted for exposure to approach artery included age, gender, hypertension, diabetes mellitus, dyslipidemia, smoking, previous MI, previous coronary artery bypass graft (CABG), PCI, chronic heart failure and previous cerebrovascular accidents (CVAs), chronic kidney disease, number of treated vessels, treated vessels \[left descending artery, left circumflex, right coronary artery (RCA), left main, ramus\], lesion characteristics (type B2 or C, bifurcation, diffuse, calcification), used drug-eluting stents type (sirolimus-eluting, paclitaxel-eluting, zotarolimus-eluting, everolimus-eluting), overlap stenting and in-hospital medication treatments (aspirin, clopidogrel, cilostazol, beta-blockers, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, and statins). The C-statistic for the logistic regression model that was used to calculate the propensity score matching for the two groups was 0.726. After PSM, the baseline covariates were compared between the two groups. Various clinical outcomes at 1 year were estimated with the Kaplan-Meier method, and differences between groups were compared with the log-rank test in the PSM patients.

RESULTS
=======

The baseline clinical characteristics of these patients are given in [Table 1](#T1){ref-type="table"}. After PSM, the baseline clinical characteristics were balanced between the two groups, except the RRA group had higher B-type natriuretic peptide (326.1±840.3 pg/mL vs. 173.4±553.0 pg/mL, *p*=0.010) ([Table 1](#T1){ref-type="table"}). The baseline angiographic and procedural characteristics are given in [Table 2](#T2){ref-type="table"}. After PSM, the baseline angiographic and procedural characteristics were balanced between the two groups, except the RRA group had larger contrast volume (259.3±119.6 mL vs. 227.0±90.7 mL, *p*\<0.001) and longer fluoroscopic time (22.5±28.0 minutes vs. 17.1±12.6 minutes, *p*=0.005) during procedure, compared with the LRA group. The procedural and in-hospital complications are given in [Table 3](#T3){ref-type="table"}. After PSM, the RRA group had higher chance of access site change (12.3% vs. 1.0%, *p*\<0.001) than the LRA group. However, procedural complications, including acute thrombosis, dissection, distal embolization, perforation, and side branch occlusion, were similar between the two groups. Access site complications, including hematoma, and in-hospital complication, including cardiogenic shock, acute renal failure, gastrointestinal bleeding, and contrast induced nephropathy, were similar between the two groups. The cumulative clinical outcomes up to 12 months are given in [Table 4](#T4){ref-type="table"}. After PSM, the cumulative clinical outcomes up to 12 months, including mortality, recurrent MI, repeat revascularization, stent thrombosis, and MACE, were similar between the two groups. However, the RRA group showed a numerically higher incidence of CVA than the LRA group, although the difference between the two groups did not reach statistical significance in-hospital (0.5% vs. 0.1%, *p*=0.624) and up to 12 months (1.1% vs. 0.2%, *p*=0.124).

DISCUSSION
==========

The TRI has reduced risk of major bleeding, improved patient comfort and convenience, and reduce inpatient time and costs, compared with TFI.[@B9][@B10] In TRI, there are clear differences in techniques, advantages, and disadvantages for the RRA and the LRA. The RRA allows for the operator to stand on the right side and has good backup force for left coronary artery. However, the RRA has poor back up force for the RCA, and it is not adequate for post CABG patients and subclavian artery tortuosity. The LRA is easy to negotiate around the arch and has good back up force for RCA. However, arm positioning of the LRA is challenging in some cases, such obese patients.[@B11][@B12] A previous study reported that the LRA is associated with a shorter learning curve, compared to the RRA.[@B11] In this study, we compared the baseline procedural characteristics between the RRA and the LRA groups using PSM analysis. RRA had larger contrast volume (259.3±119.6 mL vs. 227.0± 90.7 mL, *p*\<0.001) and longer fluoroscopic time (22.5±28.0 minutes vs. 17.1±12.6 minutes, *p*=0.005) during the procedure, compared with LRA.

In this study, the RRA group had higher chance of access site change (12.3% vs. 1.0%, *p*\<0.001), which seems to be due to difficulty in catheter manipulation, which is particularly troublesome for operators with less experience. However, procedural complications, including acute thrombosis, dissection, distal embolization, perforation, and side branch occlusion, were similar between the two groups. Also access site complications, including hematoma, and in-hospital complication, including cardiogenic shock, acute renal failure, gastrointestinal bleeding, and contrast induced nephropathy, were similar between the two groups. Therefore, we suggest that although RRA had larger contrast volume and longer fluoroscopic time during procedure, compared with LRA, both are safe and effective treatments.

In this study, after PSM, the mortality, recurrent MI, repeat revascularization, stent thrombosis, and MACE, were similar between the two groups. However, although the incidence of CVA (stroke and transient ischemic attacks) was numerically higher in the RRA group, compared to the LRA group, it was not statistically significant in-hospital (0.5% vs. 0.1%, *p*=0.624) and up to 12 months (1.1% vs. 0.2%, *p*=0.124).

In RRA, catheters have to pass the opening of the right brachiocephalic artery and bend sharply into the ascending aorta, which may disrupt atherosclerotic plaques with subsequent embolization.[@B13] Also, the longer duration of angiography with RRA contribute an additional embolic source, compared with LRA.[@B13][@B14] Stroke event rates in the general population were 0.4%, and similar results have also been obtained in previous studies where the trans-femoral approach was used: Fuchs, et al.[@B15] reported a stroke event rate of 0.38%. A similar stroke rate was observed in the reports from Emory University (0.05--0.38%)[@B16] and the Cleveland Clinic (0.3%).[@B17] Lund, et al.[@B14] reported that TRI generated significantly more particulate microemboli than TFI. Therefore, in the present study, we suggest that the choice of the LRA may be helpful to reduce the incidence of CVA during TRI.

The present study has several limitations. First, the present study was an observational study and was multicenter based retrospective in design. Because of the design of this study, a cause-result relationship was not established. Second, because this study was not randomized, the operator or center can act as a bias to analyze outcomes of this study. Procedure time, amount of contrast media, and even CVA complication rate could be quite different per operator or center. However, unfortunately, the distributions of RRA and LRA per center were not analyzed, and center or operator factor cannot be ruled out. Therefore, in a future study on the approaching method of PCI, center or operator factors must be mentioned.

In reality, there are some obstacles to performing LRA PCI, because it is difficult for operators to puncture the LRA from the right side of the patient, especially if the patient is obese. Further, the left arm should be abducted to the greatest possible extent towards the operator and placed on a comfortable support for operator\'s convenience. Therefore, if a craterization room can be set up for operator to be standing on the left side of the patient, LRA could be considered much easier.

In conclusion, while procedural efficacy, including procedural time and contrast volume, were increased and vascular access site change was more frequent in RRA, the incidence of procedural, in-hospital complications, and cumulative clinical outcomes up to 12 months were similar between the two procedures. Therefore, we suggest that LRA seems to be more effective vascular access route than RRA for TRI, although the safety of the two is similar, at least for 12 months.
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###### Baseline Clinical Characteristics
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  Variables, n (%)      Entire patients   After PSM patients                                         
  --------------------- ----------------- -------------------- --------- ------------- ------------- -------
  Male                  538 (67.9)        519 (60.2)           0.001     363 (66)      347 (63)      0.313
  Age, yrs              64.3±11.2         66.7±10.9            \<0.001   65.1±11.2     65.2±10.7     0.872
  Systolic BP (mm Hg)   126.6±21.2        128.4±18.9           0.109     127.5±21.1    127.7±18.3    0.852
  Dystolic BP (mm Hg)   76.4±13.2         77.2±11.9            0.314     76.8±13.2     77.2±11.5     0.659
  Heart rate            73.2±13.3         74.7±13.9            0.054     73.1±13.0     74.9±14.1     0.054
  LVEF (%)              58.2±10.8         56.3±12.8            0.100     58.1±10.9     57.0±12.2     0.337
  Diagnosis                                                                                          
   MI                   246 (31.0)        252 (29.2)           0.428     166 (30.1)    155 (28.1)    0.466
   STEMI                108 (13.6)        134 (15.5)           0.268     80 (14.5)     72 (13.0)     0.485
   NSTEMI               138 (17.4)        118 (13.7)           0.037     86 (15.6)     83 (15.0)     0.802
   Stable angina        170 (21.4)        201 (23.3)           0.360     124 (22.5)    130 (23.6)    0.668
   Unstable angina      336 (42.4)        351 (40.7)           0.494     232 (42.1)    239 (43.4)    0.670
   Hypertension         506 (63.8)        550 (63.8)           0.997     347 (63.0)    344 (62.5)    0.852
   Diabetes             239 (30.1)        316 (36.7)           0.005     186 (33.8)    182 (33.0)    0.798
   Dyslipidemia         241 (30.4)        254 (29.5)           0.68      149 (27.0)    146 (26.5)    0.838
   CVA                  46 (5.8)          56 (6.5)             0.557     38 (6.9)      28 (5.0)      0.204
   Heart failure        32 (4.0)          24 (2.7)             0.160     17 (3.0)      18 (3.2)      0.864
   PAD                  11 (1.3)          10 (1.1)             0.680     10 (1.8)      8 (1.4)       0.635
   CKD                  17 (2.1)          31 (3.6)             0.079     16 (2.9)      16 (2.9)      1.000
   Dialysis             7 (0.8)           5 (0.5)              0.468     7 (1.2)       5 (0.9)       0.562
   Smoking              420 (53.0)        406 (47.1)           0.017     279 (50.7)    265 (48.1)    0.399
   Current smoking      280 (35.3)        247 (28.6)           0.004     169 (30.7)    167 (30.3)    0.896
   Previous MI          75 (9.4)          64 (7.4)             0.136     44 (8.0)      37 (6.7)      0.419
   Previous CABG        6 (0.7)           1 (0.1)              0.060     0 (0.0)       1 (0.1)       1.000
   Previous PCI         144 (18.1)        140 (16.2)           0.301     99 (18)       91 (16.5)     0.523
  Laboratory findings                                                                                
   HbA1c                6.4±1.3           6.6±1.3              0.069     6.5±1.2       6.5±1.3       0.394
   CK-MB                21.5±94.3         14.8±61.3            0.101     23.9±108.7    15.0±69.9     0.118
   Troponin I           2.9±11.4          7.8±130.3            0.398     3.6±12.8      10.4±166.7    0.440
   Troponin T           0.2±1.4           0.2±1.2              0.546     0.2±1.5       0.2±1.0       0.837
   BNP (pg/mL)          323.3±875.2       211.0±604.2          0.026     326.1±840.3   173.4±553.0   0.010
   hs CRP (mg/dL)       1.6±8.3           1.9±11.5             0.497     1.4±9.2       2.1±14.       0.374
   Creatinine (mg/dL)   0.9±0.3           0.9±0.4              0.272     0.9±0.4       0.9±0.5       0.666

PSM, propensity score matched; BP, blood pressure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non ST-segment elevation myocardial infarction; CVA, cerebrovascular accident; PAD, peripheral artery disease; CKD, chronic kidney disease; CABG, coronary bypass graft; PCI, percutaneous coronary intervention; HbA1c, hemoglobin A1c; CK-MB, creatine kinase MB; BNP, B-type natriuretic peptide; hs CRP, high sensitivity C-reactive protein.

Continuous variables are given as the mean SD; categorical variables are given as counts, with percentages in parentheses.

###### Baseline Angiographic and Procedural Characteristics
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  Variables, n (%)             Entire patients   After PSM patients                                        
  ---------------------------- ----------------- -------------------- --------- ------------- ------------ ---------
  Target lesion                                                                                            
   LAD                         457 (57.7)        484 (56.2)           0.542     320 (58.1)    304 (55.2)   0.330
   LCx                         129 (16.2)        174 (20.2)           0.040     103 (18.7)    106 (19.2)   0.818
   RCA                         369 (46.5)        398 (46.2)           0.882     241 (43.8)    251 (45.6)   0.544
   Left main                   23 (2.9)          40 (4.6)             0.065     18 (3.2)      22 (4.0)     0.519
  Lesion characteristics                                                                                   
   TypeB2/C                    590 (74.4)        602 (69.9)           0.038     391 (71.0)    389 (70.7)   0.894
   Bifurcation                 214 (27.0)        173 (20.0)           0.001     123 (22.3)    119 (21.6)   0.771
   Diffuse (\>2 cm)            307 (38.7)        310 (36.0)           0.247     200 (36.3)    204 (37.0)   0.802
   Calcification               57 (7.1)          172 (19.9)           \<0.001   53 (9.6)      56 (10.1)    0.762
  Multivessel disease^\*^      185 (23.3)        227 (26.3)           0.158     129 (23.4)    133 (24.1)   0.777
  Chronic total occlusion      51 (6.4)          75 (8.7)             0.082     40 (7.2)      38 (6.9)     0.814
  Stent type                                                                                               
   SES                         74 (9.3)          84 (9.7)             0.776     56 (10.1)     53 (9.6)     0.762
   PES                         412 (52.0)        325 (37.7)           \<0.001   235 (42.7)    243 (44.1)   0.627
   ZES                         181 (22.8)        333 (38.6)           \<0.001   164 (29.8)    173 (31.4)   0.556
   EES                         293 (36.9)        322 (37.3)           0.865     224 (40.7)    212 (38.5)   0.459
  Procedural characteristics                                                                               
   Adjuvant ballooning         599 (75.6)        590 (68.5)           0.001     398 (72.3)    371 (67.4)   0.076
   LMWH                        194 (24.4)        167 (19.3)           0.012     115 (20.9)    111 (20.1)   0.765
   GpIIb/IIIa inhibitor        20 (2.5)          46 (5.3)             0.003     17 (3.0)      15 (2.7)     0.720
   Contrast volume (mL)        268.3±119.7       228.4±92.3           \<0.001   259.3±119.6   227.0±90.7   \<0.001
   F-time (min)                21.6±26.1         17.0±12.4            0.004     22.5±28.0     17.1±12.6    0.005

PSM, propensity score matched; LAD, left anterior descending artery; LCx, left circumflex artery; RCA, right coronary artery; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; ZES, zotarolimus-elution stent; EES, everolimus-elution stent; LMWH, low molecular weight heparin; GpIIb/IIIa inhibitor, glycoprotein IIb/IIIa inhibitors; F- time, fluoroscopic time.

Continuous variables are given as the mean SD; categorical variables are given as counts, with percentages in parentheses.

^\*^Number of coronary arteries narrowed \>2.

###### Procedural and In-Hospital Complications
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  Variables, n (%)                Entire patients   After PSM patients                                     
  ------------------------------- ----------------- -------------------- --------- ----------- ----------- ---------
  Procedural complications        65 (8.2)          88 (10.2)            0.158     49 (8.9)    58 (10.5)   0.360
   Acute thrombosis               2 (0.2)           3 (0.3)              1.000     1 (0.1)     2 (0.3)     1.000
   Distal embolization            2 (0.2)           1 (0.1)              0.610     2 (0.3)     0 (0.0)     0.500
   Perforation                    3 (0.3)           1 (0.1)              0.355     1 (0.1)     1 (0.1)     1.000
   Side branch occlusion          24 (3.0)          42 (4.8)             0.055     19 (3.4)    30 (5.4)    0.108
   No reflow                      20 (2.5)          20 (2.3)             0.789     18 (3.2)    10 (1.8)    0.126
  Access site complications                                                                                
   Access site change             80 (10.1)         10 (1.1)             \<0.001   68 (12.3)   6 (1.0)     \<0.001
   Hematoma                       7 (0.8)           10 (1.1)             0.576     4 (0.7)     4 (0.7)     1.000
    Minor hematoma (\<4 cm)       7 (0.8)           10 (1.1)             0.576     4 (0.7)     4 (0.7)     1.000
    Major hematoma (≥4 cm)        0 (0.0)           0 (0.0)              1.000     0 (0.0)     0 (0.0)     1.000
  In-hospital complications                                                                                
   Cardiogenic shock              20 (2.5)          19 (2.2)             0.670     15 (2.7)    12 (2.1)    0.559
   Acute renal failure            0 (0.0)           4 (0.4)              0.126     0 (0.0)     4 (0.7)     0.124
   Acute heart failure            9 (1.1)           9 (1.0)              0.859     6 (1.0)     6 (1.0)     1.000
   Cerebrovascular accident       4 (0.5)           2 (0.2)              0.435     3 (0.5)     1 (0.1)     0.624
   Gastrointestinal bleeding      5 (0.6)           8 (0.9)              0.493     3 (0.5)     4 (0.7)     1.000
   Transfusion                    29 (3.6)          41 (4.7)             0.267     17 (3.0)    27 (4.9)    0.124
   Transfusion (pint)             4.3±7.6           2.3±1.8              0.172     4.5±9.7     2.2±2.0     0.358
   Contrast reaction              5 (0.6)           12 (1.3)             0.125     2 (0.3)     6 (1.0)     0.287
   Contrast induced nephropathy   5 (0.6)           11 (1.2)             0.180     2 (0.3)     5 (0.9)     0.452

PSM, propensity score matched.

Continuous variables are given as the mean SD; categorical variables are given as counts, with percentages in parentheses.

###### Cumulative Clinical Outcomes Up to 12 Months
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  Variables, n (%)        Entire patients   After PSM patients                                 
  ----------------------- ----------------- -------------------- ------- ---------- ---------- -------
  Outcomes at 30 days                                                                          
   Total death            22 (2.7)          29 (3.3)             0.488   14 (2.5)   12 (2.1)   0.691
    Cardiac death         21 (2.6)          25 (2.9)             0.756   14 (2.5)   11 (2.0)   0.544
    Non-cardiac death     1 (0.1)           4 (0.4)              0.376   0 (0.0)    1 (0.1)    1.000
   Recurrent MI           1 (0.1)           1 (0.1)              1.000   1 (0.1)    1 (0.1)    1.000
    NSTEMI                1 (0.1)           1 (0.1)              1.000   1 (0.1)    1 (0.1)    1.000
   Revascularizations     6 (0.7)           5 (0.5)              0.659   5 (0.9)    3 (0.5)    0.726
   TLR                    6 (0.7)           5 (0.5)              0.659   5 (0.9)    3 (0.5)    0.726
   TVR                    6 (0.7)           5 (0.5)              0.659   5 (0.9)    3 (0.5)    0.726
   Stent thrombosis       6 (0.7)           6 (0.6)              0.885   5 (0.9)    3 (0.5)    0.726
  Outcomes at 12 months                                                                        
   Total death            31 (3.9)          52 (6.0)             0.048   21 (3.8)   26 (4.7)   0.456
    Cardiac death         23 (2.9)          36 (4.2)             0.162   15 (2.8)   16 (2.9)   0.855
    Non-cardiac death     8 (1.0)           16 (1.8)             0.150   6 (1.0)    10 (1.8)   0.314
   Recurrent MI           3 (0.3)           5 (0.5)              0.728   3 (0.5)    3 (0.5)    1.000
    STEMI                 0 (0.0)           1 (0.1)              1.000   0 (0.0)    1 (0.1)    1.000
    NSTEMI                3 (0.3)           4 (0.4)              1.000   3 (0.5)    2 (0.4)    1.000
   Revascularizations     33 (4.1)          46 (5.3)             0.263   25 (4.5)   27 (4.9)   0.776
   TLR                    23 (2.9)          36 (4.1)             0.162   17 (3.0)   23 (4.1)   0.334
   TVR                    33 (4.1)          43 (4.9)             0.422   25 (4.5)   27 (4.9)   0.776
   Stent thrombosis       6 (0.7)           7 (0.8)              0.899   5 (0.9)    3 (0.5)    0.726
   CVA                    9 (1.1)           2 (0.2)              0.024   6 (1.1)    1 (0.2)    0.124
   MACE                   61 (7.7)          97 (11.2)            0.014   44 (8.0)   53 (9.6)   0.339
   MACCE                  70 (8.8)          97 (11.2)            0.102   50 (9.1)   53 (9.6)   0.756

PSM, propensity score matched; MI, myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non ST-segment elevation myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization; CVA, cerebrovascular accident; MACE, major adverse cardiovascular events; MACCE, major adverse cerebrovascular events.

Continuous variables are given as the mean SD; categorical variables are given as counts, with percentages in parentheses.
